World Psoriasis Pipeline Insight Report 2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Psoriasis Pipeline Insight 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Psoriasis - Pipeline Insight, 2021," report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
A major population of patients can get benefitted from the topical therapies; this can also be initiated at the primary care level. If these particular topical agents do not provide an adequate response, the patients can be further referred to a dermatologist, at this particular point systemic therapy with topical adjuncts might be more beneficial. Presence of psoriatic arthritis involves systemic therapies in collaboration with a rheumatologist.
"Psoriasis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriasis pipeline landscape is provided which includes the disease overview and Psoriasis treatment guidelines.
The assessment part of the report embraces, in depth Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
- The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriasis.
- In November 2020, Biohaven Pharmaceutical collaborates with Weill Cornell Medicine, to initiate a clinical trial with a Biohaven CGRP-receptor antagonist for the treatment of plaque psoriasis. CGRP is a neuropeptide and believed to play an important role in the pathogenesis of inflammatory skin diseases such as psoriasis.
Psoriasis Emerging Drugs Chapters
This segment of the Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Psoriasis Emerging Drugs
Topical roflumilast: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). The therapy is in Phase III clinical development for the treatment of Plaque Psoriasis.
GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. The molecule is in Phase I clinical development for the treatment of Psoriasis.
Psoriasis: Therapeutic Assessment
This segment of the report provides insights about the different Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Psoriasis
There are approx. 130+ key companies which are developing the therapies for Psoriasis. The companies which have their Psoriasis drug candidates in the most advanced stage, i.e. Registered include, Biocad.
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as:
- Molecule Type
Products have been categorized under various Molecule types such as:
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Psoriasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Psoriasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriasis drugs.
Psoriasis Report Insights
- Psoriasis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Psoriasis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Psoriasis drugs?
- How many Psoriasis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Psoriasis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Psoriasis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bristol-Myers Squibb
- Coherus BioSciences
- Janssen Pharmaceuticals
- Can-Fite Biopharma
- Arcutis Biotherapeutics
- Iltoo Pharma
- Galectin Therapeutics
- Evelo Biosciences
- BioMimetix JV
- Menlo Therapeutics Inc.
- Aristea Therapeutics
- UNION Therapeutics
- Sienna Biopharmaceuticals
- ABP 654
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8yxnl5
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900